English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 912449      Online Users : 1197
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version
    國家衛生研究院 NHRI > 癌症研究所 > 其他 > 期刊論文 >  Item 3990099045/3063


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/3063


    Title: Biodistribution, pharmacokinetics and imaging of Re-188-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model
    Authors: Chen, LC;Chang, CH;Yu, CY;Chang, YJ;Hsu, WC;Ho, CL;Yeh, CH;Luo, TY;Lee, TW;Ting, G
    Contributors: National Institute of Cancer Research
    Abstract: Nanoliposomes are important carriers capable of packaging drugs for various delivery applications through passive targeting tumor sites by enhanced permeability and retention effect. Radiolabeled liposomes have potential applications in radiotherapy and diagnostic imaging. The purpose of this study was to investigate the biodistribution, pharmacokinetics and imaging of nanotargeted Re-188-N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-labeled pegylated liposomes (RBLPL) and unencapsulated Re-188-BMEDA after intraperitoneal (ip) injection in a C26 colon carcinoma ascites mouse model. The nanopegylated liposomes were labeled with Re-188-BMEDA. The labeling efficiency of RBLPL was 82.3 +/- 4.5%. In vitro stability of RBLPL in normal saline at room temperature and in rat plasma at 37 degrees C for 72 h was 92.01 +/- 1.31% and 82.4 +/- 1.64%, respectively. The biodistribution studies indicated that the radioactivity in ascites was 69.96 +/- 14.08 percentage injected dose per gram (% ID/g) at 1 h to 5.99 +/- 1.97% ID/g at 48 h after ip administration of RBLPL. The levels of radioactivity in tumor were progressive accumulation to a maximum of 6.57 +/- 1.7% ID/g at 24 h. The radioactivity of Re-188-BMEDA in ascites reached the maximum level of 54.89 +/- 5.91% ID/g at 1 h and declined rapidly with time. Pharmacokinetic studies revealed that the terminal half-life, total body clearance and area under the curve of RBLPL were 5.3-, 9.5- and 9.4-fold higher than that of Re-188-BMEDA in blood, respectively. These results suggested that the long circulation, bioavailability and localization of RBLPL in tumor and ascites sites, which also demonstrate that the ip administration of RBLPL is a potential multifunctional nanoradiotherapeutics and imaging agents on a C26 colon carcinoma ascites mouse model.
    Keywords: Radiology, Nuclear Medicine & Medical Imaging
    Date: 2007-05
    Relation: Nuclear Medicine and Biology. 2007 May;34(4):415-423.
    Link to: http://dx.doi.org/10.1016/j.nucmedbio.2007.02.003
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0969-8051&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000246775600009
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=34248153759
    Appears in Collections:[其他] 期刊論文

    Files in This Item:

    File Description SizeFormat
    000246775600009.pdf266KbAdobe PDF697View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback